Hypertension, nonsteroidal antiinflammatory drugs, and lessons learned

Journal of Rheumatology

Volumn 31, Issue 6, 2004, Pages 1035-1037

  Pope, Janet E ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CELECOXIB; DIURETIC AGENT; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULINDAC;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DRUG DOSE REDUCTION; DRUG USE; EDITORIAL; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTOLIC BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; NOTE; RHEUMATIC DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYPERTENSION; RHEUMATIC DISEASES;

EID: 4444378434     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
2. Nguyen-Oghalai TU, Fyr CW, Criswell LA. Inadequate detection and treatment of hypertension in rheumatoid arthritis [abstract]. Arthritis Rheum. 2003;48 Suppl:S320.
3. Wolfe F, Zhao S, Reynolds M, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, non-selective NSAID and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 2004;31:1143-51.
4. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
5. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure. A meta-analysis. Ann Intern Med 1994;121:289-300.
6. Fujita T, Yamashita N, Yamashita K. Effect of indomethacin on antihypertensive action of captopril in hypertensive patients. Clin Exp Hypertens 1981;3:939-52.
7. Covi G, Minuz P, Capuzzo G, Lechi C, Delva P, Lechi A. Reduction of the antihypertensive effect of captopril induced by prostaglandin synthetase inhibition. Int J Clin Pharmacol Res 1984;4:47-52.
8. Seto S, Aoi W, Iwami K, et al. Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension. Clin Exp Hypertens A 1987;9:623-7.
9. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987;5:121-8.
10. Higashimori K, Gante J, Holzemann G, Inagami T. Significance of vascular renin for local generation of angiotensins. Hypertension 1991;17:270-7.
11. Ashida T, Nishioeda Y, Kimura G, et al. Effects of salt, prostaglandin, and captopril on vascular responsiveness in essential hypertension. Am J Hypertens 1989;2:640-2.
12. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95. Erratum in: Am J Ther 2001;8:220.
13. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95. Erratum in: Am J Ther 2001;8:220.
14. Whelton A, White WB, Bello AE, Puma JA, Fort JG. SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
15. Nietert PJ, Ornstein SM, Dickerson LM, Rothenberg RJ. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy 2003;23:1416-23.
16. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61.
17. Bombardier C, Laine L, Reicin A, et al. The VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
18. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program [review]. Am Heart J 2003;146:591-604.
19. Senthilselvan A. Prevalence of physician-diagnosed asthma in Saskatchewan, 1981 to 1990. Chest 1998;114:388-92.